Zacks: Brokerages Anticipate G1 Therapeutics, Inc. (NASDAQ:GTHX) Will Post Quarterly Sales of $5.58 Million

Brokerages expect that G1 Therapeutics, Inc. (NASDAQ:GTHX) will announce $5.58 million in sales for the current fiscal quarter, according to Zacks. Five analysts have made estimates for G1 Therapeutics’ earnings. The lowest sales estimate is $5.20 million and the highest is $6.71 million. G1 Therapeutics posted sales of $16.55 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 66.3%. The business is scheduled to report its next earnings results on Wednesday, February 23rd.

On average, analysts expect that G1 Therapeutics will report full year sales of $31.26 million for the current fiscal year, with estimates ranging from $30.90 million to $32.39 million. For the next financial year, analysts forecast that the firm will report sales of $46.58 million, with estimates ranging from $38.64 million to $58.92 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow G1 Therapeutics.

G1 Therapeutics (NASDAQ:GTHX) last released its earnings results on Wednesday, November 3rd. The company reported ($1.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.03) by $0.03. G1 Therapeutics had a negative return on equity of 65.66% and a negative net margin of 316.58%. During the same quarter in the previous year, the company earned ($0.31) earnings per share.

Several analysts recently issued reports on the company. HC Wainwright cut their target price on G1 Therapeutics from $78.00 to $71.00 and set a “buy” rating for the company in a research report on Thursday, November 4th. JPMorgan Chase & Co. cut G1 Therapeutics from a “neutral” rating to an “underweight” rating and cut their price target for the company from $20.00 to $19.00 in a report on Thursday, November 4th. Raymond James cut their price target on G1 Therapeutics from $41.00 to $24.00 and set an “outperform” rating for the company in a report on Thursday, November 4th. Zacks Investment Research upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, November 8th. Finally, Wedbush lowered their price objective on G1 Therapeutics from $59.00 to $38.00 and set an “outperform” rating for the company in a research note on Thursday, August 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $42.43.

Several large investors have recently made changes to their positions in the company. BlackRock Inc. increased its holdings in shares of G1 Therapeutics by 0.4% in the 3rd quarter. BlackRock Inc. now owns 3,242,085 shares of the company’s stock valued at $43,508,000 after acquiring an additional 12,319 shares during the period. State Street Corp increased its holdings in shares of G1 Therapeutics by 1.5% in the 2nd quarter. State Street Corp now owns 2,771,047 shares of the company’s stock valued at $60,797,000 after acquiring an additional 40,111 shares during the period. Vanguard Group Inc. increased its holdings in shares of G1 Therapeutics by 2.5% in the 2nd quarter. Vanguard Group Inc. now owns 2,502,826 shares of the company’s stock valued at $54,912,000 after acquiring an additional 61,841 shares during the period. JPMorgan Chase & Co. grew its stake in G1 Therapeutics by 2.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,876,160 shares of the company’s stock worth $41,162,000 after buying an additional 48,271 shares during the last quarter. Finally, Fisher Asset Management LLC grew its stake in G1 Therapeutics by 90.0% during the 3rd quarter. Fisher Asset Management LLC now owns 1,738,211 shares of the company’s stock worth $23,327,000 after buying an additional 823,373 shares during the last quarter. Institutional investors and hedge funds own 64.04% of the company’s stock.

Shares of NASDAQ:GTHX remained flat at $$13.66 during trading on Thursday. The company had a trading volume of 470,240 shares, compared to its average volume of 1,155,083. The company has a debt-to-equity ratio of 0.17, a quick ratio of 8.63 and a current ratio of 8.68. G1 Therapeutics has a 12-month low of $11.98 and a 12-month high of $37.07. The firm has a 50-day moving average of $14.07 and a 200-day moving average of $17.07. The firm has a market capitalization of $580.85 million, a P/E ratio of -4.19 and a beta of 2.16.

About G1 Therapeutics

G1 Therapeutics, Inc engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Recommended Story: How to Use the MarketBeat Retirement Calculator

Get a free copy of the Zacks research report on G1 Therapeutics (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.